Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 9

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 9
---
 pipeline
of products that can be used for additional tissue regeneration opportunities.

<div align='center'>2</div>

Summary Risk Factors Investing in our securities involves substantial risk. The risks described under the heading “Risk Factors” immediately following this summary may cause us to not realize the full benefits of our strengths or may cause us to be unable to successfully execute all or part of our strategy. Some of the more significant challenges include the following: Risks Related to Our Financial Condition and Capital Requirements

| ● | We have a limited operating                                                                                                       
 history and we have incurred significant operating losses since our inception, and anticipate that we will incur continued losses 
 for the foreseeable future. We have not generated any revenue from product sales and may never be profitable.                     |

| ● | Even if this offering is                                                                                                             
 successful, we will need to raise substantial additional funding, which may not be available on acceptable terms, or at all. Failure 
 to obtain funding on acceptable terms and on a timely basis may require us to curtail, delay or discontinue our product development  
 efforts or other operations.                                                                                                         |
| ● | Our financial statements                                                                                                             
 contain an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern, which could prevent   
 us from obtaining new financing on reasonable terms or at all.                                                                       |

Risks Related to Our Business and Industry

| ● | We may not succeed in advancing                                                                                                         
 the development of our product, achieve manufacturing stability and capacity, demonstrate sufficient clinical evidence or commercialize 
 our product and generate significant revenues.                                                                                          |

| ● | Clinical failure can occur                                                                                                                
 at any stage of clinical development. Our clinical experience to date does not necessarily predict future results and may not have        
 revealed certain potential limitations of the technology and potential complications from GelrinC and may require further clinical        
 validation. Any product version we advance through clinical trials may not have favorable results in later clinical trials or may         
 not receive a regulatory approval.                                                                                                        |
| ● | We operate in a very competitive                                                                                                          
 business environment, and if we are unable to compete successfully against our existing or potential competitors, our business, financial 
 condition and results of operations may be adversely affected.                                                                            |

| ● | We expect to derive most                                                                                                                
 of our revenues from the sales of GelrinC. Our inability to successfully commercialize this product candidate or any subsequent decline 
 in demand for this product candidate, could severely harm our ability to generate revenues.                                             |
| ● | If healthcare professionals                                                                                                             
 do not